1. Economics of chronic hepatitis B and hepatitis C
Arathi Rajendra, John B. Wong 
Journal of Hepatology 
Volume 47, Issue 4, Pages (October 2007)
DOI: /j.jhep
Copyright © 2007 European Association for the Study of the Liver Terms and Conditions

2. Fig. 1
Cost-effectiveness plot of antiviral treatment for chronic hepatitis B [52]: This graph displays lifetime costs and quality-adjusted life years associated with single and sequential antiviral treatments for chronic hepatitis B [52]. The lines define the cost-effectiveness frontier. Any points above the line are inferior and excluded by dominance or extended dominance. The slopes of the lines equal the incremental cost-effectiveness ratio between any two strategies. Abbreviations: S, supportive care; I, Interferon; L, lamivudine; PI, peginterferon; A, adefovir.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2007 European Association for the Study of the Liver Terms and Conditions